Navigation Links
Hepatitis C Drug Market: Forecasts for 9 Countries, Players' (Current and Future) Analysis in New Research Reports

DALLAS, June 13, 2013 /PRNewswire-iReach/ -- now offers new market research reports on the Hepatitis C Virus drug industry for US, Japan, Brazil China, France, Germany, Italy, Spain and the UK with an in-depth analysis on the companies in these countries. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir).


In United States, the projected drivers of HCV drug market growth include increased patient awareness of HCV, broader HCV screening recommendations, the shift in American medicine toward preventative care, and the launch of next-generation HCV therapies. The report "PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis" ( says Vertex's Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek's improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the drug to quickly capture the market. The adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

Standard interferon drugs are the current market leader in China as per the report "PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis" ( Primary research done for this report revealed that Merck's Intron A (interferon alfa-2b) is the most commonly prescribed standard interferon in China, but that Roferon-A (interferon alfa-2a) and Kadmon's Infergen (interferon alfacon-1) are also used frequently. Standard interferon requires more-frequent dosing than peginterferon alpha, but standard interferon has been able to retain its market share in China in the face of competition from peginterferon due to its lower cost.

The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies. The report "PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis" ( says Roche's Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck's PegIntron (peginterferon alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country's HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug's inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin).

"PharmaPoint: Hepatitis C Virus – Japan Drug Forecast and Market Analysis" ( says Merck's PegIntron (peginterferon alfa-2b) is the current market leader in Japan. The current standard of HCV therapy in Japan is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, PegIntron directly competes for market share with Roche's Pegasys (peginterferon alfa-2a). GlobalData's primary research revealed that peginterferon market position is further bolstered by the frequent use of interferon monotherapy in Japan.

Janssen's Incivo is the current market leader in the UK Hepatitis C Virus drug market as per the report "PharmaPoint: Hepatitis C Virus – United Kingdom Drug Forecast and Market Analysis" @ Incivo was among the first DAA HCV therapies launched in the UK. The regimen had an improved efficacy compared with the previous standard of care for HCV GT1, a combination of peginterferon and ribavirin. GlobalData assumes that Incivo's shorter duration of triple-therapy (i.e., DAA, peginterferon, and ribavirin) compared with Merck's Victrelis enabled it to outcompete Victrelis for market share. Incivo and Victrelis are both associated with adverse events, which has resulted in HCV-infected patients in the UK deciding to forego therapy in order to await the launch of more-tolerable HCV therapies.

Other country reports available on the Hepatitis C Virus drug market forecasts:

On the same lines, a different but relevant report "PharmaPoint: Hepatitis C Virus – Current and Future Players" @ is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HCV Market. The report identifies and analyses the key companies shaping and driving the global HCV market. The report provides insight into the competitive HCV landscape, including new companies entering the market. Companies covered in this report include Merck, Roche, Vertex, Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Mitsubishi Tanabe, GlaxoSmithKline, Achillion, Scynexis, Idenix and Presidio. Order / Buy a copy of this report @

Explore more reports on the Hepatitis Drugs Market @

About Us: is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore more market research reports @

Media Contact: Priyank Tiwari RnR Market Research, +1 888 391 5441,

News distributed by PR Newswire iReach:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
3. Bulgaria Launches Development of National Hepatitis Plan
4. Major Breakthrough in Hepatitis C Vaccine Development
5. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):